Overview

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a second generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to eliminate blood-brain barrier penetration and subsequent brain CB1 receptor occupancy that mediates the neuropsychiatric adverse events associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include nonalcoholic steatohepatitis, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

Management Team

Yuval Cohen, PhD  
Chief Executive Officer, Director

Craig Millian, MBA  
Chief Commercial Officer

Sean Moran, CPA, MBA  
Chief Financial Officer

Barbara White, MD  
Chief Medical Officer

Robert Discordia, Ph.D.  
Vice President, Pharmaceutical Development & Manufacturing

Ross Lobell  
Vice President, Regulatory Affairs

Recent News

Monday, December 09, 2019 - 08:05 AM  
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

Monday, November 18, 2019 - 08:17 AM  
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

Tuesday, November 12, 2019 - 08:05 AM  
Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

Monday, November 11, 2019 - 08:05 AM  
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

Thursday, November 07, 2019 - 07:05 AM  
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.